NYSE · Healthcare · Medical Instruments & Supplies

Becton, Dickinson and Company (BDX)

As of Sep 25, 4:00 PM ET, Becton, Dickinson and (BDX) last traded at $183.82, up 2.56% on the day. Its TickerHum research score is 53/100 (average). It reported revenue of $22.48B for the twelve months ending 2026-06-30, up 18.5% year over year, with a 10.7% operating margin.

Ratings

Reported fundamentals

MetricValuePeriod
Revenue$22.48BTTM ending 2026-06-30 · 10-Q
Revenue growth18.5%TTM ending 2026-06-30 · 10-Q
Net income$942MTTM ending 2026-06-30 · 10-Q
Diluted EPS$3.31TTM ending 2026-06-30 · 10-Q
Gross margin33.7%FY ending 2020-09-30 · 10-K
Operating margin10.7%TTM ending 2026-06-30 · 10-Q
Net margin4.2%TTM ending 2026-06-30 · 10-Q
Free cash flow$3.89BFY ending 2021-09-30 · 10-K
Cash$708Mas of 2026-06-30 · 10-Q
Long-term debt$13.51Bas of 2026-06-30 · 10-Q
Debt / equity0.55as of 2026-06-30 · 10-Q

Source: SEC EDGAR XBRL company facts (CIK 0000010795).

Compare Becton, Dickinson and with its closest competitors

Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.